MUNICH & LANGHORNE, Pa.--(BUSINESS WIRE)--Priaxon AG and its collaboration partner Nexuspharma Inc announce the presentation of preclinical results from their novel mdm2/p53-inhibitor program at the AACR in Denver on April 19th, 2009. Priaxon has developed a series of novel and potent inhibitors of the mdm2-p53 protein-protein interaction by applying its unique Multi-Component-Reaction chemistry and chemoinformatic tool kit. Nexuspharma offers unique expertise in cancer biology research and preclinical development. Dr. Vladimir Khazak, Director, Biology of Nexuspharma will present the comprehensive data on selectivity, drug-like characteristics, and in vitro- and in-vivo activity for the Priaxon Mdm2 inhibitors.
